Theravance Biopharma (TBPH) Current Assets (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Current Assets data on file, last reported at $417.6 million in Q1 2026.

• Current Assets for Q1 2026 came in at $417.6 million, up 177.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $417.6 million (up 177.93% YoY), and the FY2025 annual result was $418.5 million, up 159.8% from the prior year.
• Current Assets steadied at $417.6 million in Q1 2026 per TBPH's latest filing, from $418.5 million in the prior quarter.
• Over five years, Current Assets peaked at $511.7 million in Q3 2022 and troughed at $116.5 million in Q3 2024.
• A 5-year average of $247.2 million and a median of $192.0 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets slumped 68.4% in 2023, then jumped 207.02% in 2025.
• A 5-year view of Current Assets shows it stood at $353.5 million in 2022, then tumbled by 62.22% to $133.5 million in 2023, then climbed by 20.61% to $161.1 million in 2024, then soared by 159.8% to $418.5 million in 2025, then decreased by 0.2% to $417.6 million in 2026.
• Business Quant data shows TBPH's Current Assets at $417.6 million in Q1 2026, $418.5 million in Q4 2025, and $354.7 million in Q3 2025.